In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
Guest Post by Roy S. Herbst, MD, PhD Yale Comprehensive Cancer Center
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015...
May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer...
Tamas A. Gonda, MD, 2014 recipient of the Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research, is examining how...
This year may indeed be the year in which a class of immunotherapeutics called PD-1 and PD-L1 inhibitors are...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
Guest Post by Scott M. Lippman, MD UC San Diego Moores Cancer Center
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...
Hear from AACR President Carlos L. Arteaga, MD, and Annual Meeting Program Committee Chairperson Lewis C. Cantley, PhD, about...
With the start of the AACR Annual Meeting 2015 only four days away, the organization is ramping up its...